How To Take A Next-Generation Conjugate Through Lead Candidate Selection And Technical Development
The field of bioconjugates holds immense promise for targeted therapies, particularly Antibody-Drug Conjugates (ADCs). However, optimizing and scaling up these complex molecules can be a significant hurdle. This webinar addresses this challenge head-on, equipping you with the critical design and process development steps to ensure the success of your next-generation bioconjugate.
Through a comprehensive exploration of key areas, you'll gain valuable insights into designing these powerful therapeutic tools. We delve into the strategies for selecting the most effective target and targeting moiety, a crucial step in directing the bioconjugate to its intended destination within the body. Furthermore, you'll explore the intricacies of crafting the linker-payload combination, ensuring the therapeutic payload is efficiently delivered to its target once the bioconjugate reaches its designated location. The webinar also addresses broader considerations for designing next-generation bioconjugates, empowering you to create even more potent and specific therapies.
Beyond design, the program delves into the critical aspects of process development and manufacturing for these advanced drugs. Discover innovative techniques for incorporating engineered cysteines into ADC manufacturing, streamlining the production process. Additionally, we'll explore cutting-edge manufacturing strategies for bioconjugates containing novel payloads, such as radioimmunoconjugates and oligonucleotide conjugates.
View the webinar below and gain the knowledge and practical guidance needed to navigate the design, development, and manufacturing of next-generation bioconjugates. This translates to a significant advantage in accelerating the path of these potentially life-saving therapies towards clinical application.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.